Filters

Neeti Sharma

Profile

Neeti Sharma is the Head, Human Resources at The George Institute for Global Health, bringing people-centric and psychology driven approach, to build an emotionally intelligent and inclusive culture.

Neeti holds a Master's degree in Psychology with specialisation in Organisational Behaviour and is MBTI Certified. With extensive experience across both corporate and non‑profit sectors, she brings a globally informed yet locally grounded perspective to the Human Resources function.

Designing and operationalising trials

The George Institute has a highly skilled team which works to conceptualise, develop, and deliver innovative and impactful clinical trials, characterised by the following features: Reducing trial ‘waste’ Ensuring that clinical trials are efficient is crucial to minimising research ‘waste’, which most commonly results from the costs associated with poorly conceived research questions, inappropriate study design, failure to adequately report on all areas being analysed, and inefficient operational conduct. Trial efficiency can be improved via two key mechanisms- by design and by conduct. Trial design involves the development and application of innovative statistical methods including adaptive and pragmatic designs. The first involves adapting some elements of the design as the trial progresses (rather than waiting for the trial to end). A pragmatic trial evaluates a health intervention in a setting as close as possible to real-world conditions. Adaptive designs help to gener

What are clinical and community trials

What are clinical trials? Clinical trials are research studies with humans, designed to test new treatments to find better ways to prevent, detect or treat disease1. Clinical trials are also sometimes referred to as interventional trials. The sorts of treatments being investigated include medicines or drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments, process-of-care changes, preventive care, and other items.2 Clinical trials rely on having members of the general public agree to take part. What happens in a clinical trial? In a clinical trial, participants meet with researchers who go through what the clinical trial will involve. All participants must be advised about the objectives of the research, what is expected of them, as well as any risks that may be experienced during and after the trial. Trials must follow a carefully controlled protocol, which is a plan that describes what researchers will do in the stu

Innovative clinical trials

Researchers at The George Institute for Global Health, UK, led by Executive Director Professor Otavio Berwanger, are spearheading a programme of work to transform that way we deliver large-scale clinical trials. This programme is borne out of a recognition of the limitations of the ‘traditional’ clinical trial model – and the health gains (social, environmental and economic) – to be had in investigating pragmatic, innovative and efficient approaches. In both the so-called ‘traditional’ and innovative trial models, the gold standard of randomisation controls for both known and unknown confounding factors that could influence trials outcomes, and represents the optimal method to work out whether a healthcare intervention reduces the risk of patient-important outcomes and so inform clinical practice. Where the two models differ is that the traditional approach requires participants be screened and recruited in a trial site by a team of investigators, and so demands both a

Connecting climate, NCDs & women’s health at Women Deliver 2026

News

Prasanthi Attwood

Profile

Prasanthi is an injury epidemiologist focusing on monitoring and evaluation of child road safety projects in 6 countries through the Botnar Foundation and working with longitudinal data to analyse gender differences and injuries amongst a large cohort of adolescents from Vietnam, Peru, Ethiopia and India.

Prasanthi obtained her medical degree from Cambridge University (UK), and then spent over a decade working within the field of injury prevention at Johns Hopkins (Baltimore, US). With a young family and move back to the UK, she wanted to be part of a dynamic and innovative team slightly closer to home and was therefore thrilled to have the opportunity to join the George Institute, UK, helping to further develop the injury research portfolio.

Session 1: Setting the Scene. The burden of childhood burns In Africa

Event

Session 2: Prevention Pathways - From home hazards to safe environments

Event

As the climate changes, how can we protect our food systems and our health?

Podcast

Whistleblower policy

1. About us The George Institute for Global Health, together with its subsidiary companies worldwide (The George Institute or TGI), is committed to the highest standards of conduct and ethical behaviour, research integrity and good corporate governance and to operating: legally and in accordance with applicable legislation and regulations; properly, in accordance with organisational policy and procedures; and ethically, in accordance with recognised ethical principles. Including: supporting Whistleblowers to make reports based on reasonable grounds of Reportable Conduct involving the Institute’s activities, including its scientific research; ensuring that any Whistleblower who makes a report based on reasonable grounds to assist in maintaining the legal, proper and ethical operations of the Institute, can do so: anonymously if they wish; without fear of intimidation, disadvantage or reprisal; and without being penalised in any w

60 Day prescriptions are saving millions. Why aren’t more Australians getting them?

News / Media release

Professor Craig Anderson

Profile

Professor Craig Anderson is Professor of Neurology and Epidemiology, Faculty of Medicine, UNSW Sydney, and is in part-time clinical practice as a neurologist at Royal Prince Alfred Hospital, Sydney, Australia.  

Craig holds specialist qualifications in clinical neurology and geriatrics, a PhD in medicine and epidemiology from The University of Western Australia, and is a Senior Investigator Fellow of the National Health and Medical Research Council (NHMRC) of Australia.  He is a past President of the Asia Pacific Stroke Organisation and the Stroke Society of Australasia, and is a member of several specialist societies and an editor for the Cochrane Stroke Group.  He has published widely on the clinical and epidemiological aspects of stroke, cardiovascular disease and aged care, and has led several large-scale investigator-initiated epidemiological and clinical trials that have had a major influence on clinical practice guidelines for stroke treatment and prevention.